Pharmaceutical Contract Manufacturing Market, by Product (Active Pharmaceutical Ingredients or Bulk drug, Final Dosage Form, Advanced Drug Delivery Products, OTC Medicines and Nutritional products, Packaging): Global Opportunity Analysis and Industry Forecast, 2023-2032

The global market for pharmaceutical contract manufacturing represents one of the fastest growing markets and it is expected to proffer enormous opportunities in the near future. Contract manufacturing contributes significantly to the overall outsourcing market, owing to its popularity and widespread adoption by pharmaceutical companies. Cost containment issues resulted from global economic constraints, have exerted extensive pressure on pharmaceutical manufacturers to reduce the cost of products. Hence, to make way out of this situation, pharma companies are looking to reduce the manufacturing cost. Contract manufacturing, as a strategic option, offers the certain benefits such as cost reduction, improved product quality, product portfolio and reduction in time to market. Contract manufacturing also support the pharmaceutical companies to focus on R&D and marketing activities by minimizing the time and efforts invested in manufacturing activity. Hence, contract manufacturing is the largely accepted trend in the recent years. HAUPT Pharma AG, Abbott Laboratories, NextPharma, Catalent Pharma Solutions, Althea Technologies, Jubilant Life Sciences Limited, Royal DSM N.V and Nipro Corp. are some of the big players of this market. Patent expiration of major therapeutic brands, growing demand for generic drugs and adoption of novel manufacturing technologies are expected to boost the growth of this market.

The global market for pharmaceutical contract manufacturing is segmented based on type of contract manufacturing and geography. Based on type of contract manufacturing, the market is segmented as, Active Pharmaceutical Ingredients (API) / Bulk drug, Final Dosage Form (FDF), advanced drug delivery products, OTC medicines and Nutritional products and     Packaging contract manufacturing. The final dosage form contract manufacturing (FDF) is expected to grow with substantial CAGR due to growing demand for generic products and rising R&D investments. Geographically, global market for pharmaceutical contract manufacturing is segmented into North America, Europe, Asia-Pacific and LAMEA. North America dominates the global contract manufacturing market, whereas, Asia-Pacific is the fastest growing market due to adoption of advanced technologies, favorable regulatory framework, reduced labor cost and availability of skilled workforce.

KEY BENEFITS

This report offers the following benefits in particular:

• In-depth coverage of drivers, restraints and opportunities within global market for pharmaceutical contract manufacturing would help professionals to better understand market behavior
• Porter’s Five Forces analysis examines the competitive structure of the global market for pharmaceutical contract manufacturing and would assist market strategists in their respective decision making process
• Pin-point analysis of geographic segments helps to identify opportunities for growth within the global market for pharmaceutical contract manufacturing
• Deep insights on key developments and regulatory framework of global market for pharmaceutical contract manufacturing would be informative for professionals in corporate sector  

  Pharmaceutical Contract Manufacturing Market, by Product Report Highlights

Aspects	Details
By Product	Active Pharmaceutical Ingredients or Bulk drug Final Dosage Form Solid Dosage Form Semi solid Dosage Form Liquid Dosage Form Advanced Drug Delivery Products OTC Medicines and Nutritional products Packaging
By Region	North America  (UNITED STATES, CANADA, MEXICO) Europe  (FRANCE, GERMANY, ITALY, SPAIN, UNITED KINGDOM, Russia, Rest of Europe) Asia-Pacific  (CHINA, JAPAN, INDIA, SOUTH KOREA, AUSTRALIA, THAILAND, MALAYSIA, INDONESIA, Rest of Asia Pacific) LAMEA  (Brazil, South Africa,, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Pfizer, Inc., Grifols S.A, Iqvia Asia Pacific, Boehringer Ingelheim GmbH, Lonza, Laboratory Corporation Of America Holdings, IQVIA, Jubilant Life Sciences Limited., Albany Molecular Research, Inc., Charles River Laboratories International, Inc.

^*Terms and Conditions Apply